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1,3-Propanediol dehydrogenase (1,3-PD-DH), encoded by the dhaT gene, is a
key enzyme in the dissimilation process for converting glycerol to 1,3-
propanediol in the human pathogen Klebsiella pneumoniae. Single colourless
crystals were obtained from a recombinant preparation of 1,3-propanediol
dehydrogenase overexpressed in Escherichia coli. The crystals belong to space
group P21, with unit-cell parameters a = 91.9, b = 226.6, c = 232.6 A ˚ ,   = 92.9 .
The crystals probably contain two decamers in the asymmetric unit, with a VM
value of 3.07 A ˚ 3 Da
 1 and an estimated solvent content of 59%. Diffraction data
were collected to 2.7 A ˚ resolution using synchrotron radiation at the ID14-4
beamline of the European Synchrotron Radiation Facility.
1. Introduction
Klebsiella pneumoniae belongs to the KES group of opportunistic
pathogens (which also includes Enterobacter and Serratia species). It
is an important cause of respiratory infections and is responsible for
signiﬁcant morbidity and mortality in immuno-compromised indivi-
duals (Carpenter, 1990; Podschun & Ullmann, 1998). Protein struc-
tures from this organism are being determined as part of the
Structural Proteomics In Europe (SPINE) programme.
K. pneumoniae posseses an extremely active metabolism under
microaerophilic conditions, being able to grow fermentatively using
glycerol as the sole carbon source in a dissimilatory pathway (Huang
et al., 2002). The central enzyme of glycerol metabolism is 1,3-
propanediol dehydrogenase (1,3-PD-DH), which is encoded by the
dhaT gene and is involved in the reductive pathway of anaerobic
glycerol dissimilation, which is essential for the use of glycerol as a
carbon source in the absence of an exogenous electron acceptor
(Biebl et al., 1998; Johnson & Lin, 1987). The dhaT gene encodes a
polypeptide of 387 amino acids with a calculated MW of 41 544 Da
and a theoretical isoelectric point of 5.9. This enzyme is part of the
dha regulon that encodes two parallel pathways. Through the
oxidative pathway, glycerol is dehydrogenated by an NAD
+-linked
enzyme, glycerol dehydrogenase type I (glyDH-I), to dihydroxy-
acetone (DHA), which is then phosphorylated by an ATP-dependent
kinase to dihydroxyacetone phosphate (DHAP; Cheng et al., 2006;
Huang et al., 2002). Through the parallel reductive pathway, glycerol
is dehydrated by a B12-dependent enzyme to form 3-hydroxy-
propionaldehyde, which is then reduced to 1,3-propanediol (1,3-PD)
by the NADH-linked oxidoreductase 1,3-propanediol dehydrogenase
(Cheng et al., 2004; O’Brien et al., 2004). The physiological reason for
1,3-PD formation could be the regeneration of NAD
+ needed by the
DHA branch of the pathway controlled by the dha regulon
(Yuanyuan et al., 2004).
There are no structures available of 1,3-propanediol dehydro-
genases. The most closely related structure to have been solved is that
of lactaldehyde 1,2-propanediol oxidoreductase from Escherichia coli
(PDB code 2bl4), which shares 44% sequence identity with
1,3-PD-DH.
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2.1. Protein expression and purification
The sequence of the dhaT gene coding for 1,3-propanediol dehy-
drogenase was ampliﬁed by the polymerase chain reaction (PCR)
from K. pneumoniae genomic DNA using KOD Hot Start DNA
polymerase (Novagen) and complementary gene-speciﬁc primers, to
which were appended sequences to facilitate ligation-independent
cloning (LIC; Aslanidis & de Jong, 1990). For LIC, the PCR-ampli-
ﬁcation products were treated with T4 DNA polymerase in the
presence of dATP to generate 50 single-stranded overhangs at both
ends of the fragment through the enzyme’s combined 30-50 exo-
nuclease and DNA polymerase activities. Complementary 50 single-
stranded overhangs were generated in the vector pET-YSBLIC by
cleavage with the restriction endonuclease BseRI and treatment with
T4 DNA polymerase in the presence of dTTP. This plasmid pET-
YSBLIC is a pET28a (Novagen) derivative that has been adapted for
LIC and adds an N-terminal hexahistidine tag to the cloned gene. The
vector and PCR products were mixed and used to transform E. coli
NovaBlue cells (Novagen). Recombinants were selected through
kanamycin resistance and colony PCR using T7 promoter and gene-
speciﬁc oligonucleotide primers to conﬁrm the presence of a correctly
sized insert; the DNA sequence was subsequently veriﬁed. The pET-
YSBLICdhaT plasmid was transformed into E. coli BL21(DE3) for
recombinant protein expression.
Six 100 ml cell cultures were grown to an OD600 of 0.6 at 310 K in
Luria–Bertani broth containing 50 mgm l
 1 kanamycin. Expression of
the full native enzyme sequence fused directly to the amino-terminal
sequence (MGSSHHHHHH) encoded by pET-YSBLIC was then
induced by the addition of isopropyl  -d-thiogalactopyranoside
(IPTG) to a ﬁnal concentration of 0.5 mM. Cells were harvested by
centrifugation and resuspended in 50 mM HEPES buffer pH 7.4
containing 1 M NaCl, 1 mM MnCl2 and 2 mM DTT (buffer A). The
cells were disrupted in a French press at 131 MPa and the cell-free
supernatant was collected by centrifugation at 30 000g in a Beckman
JA-20 rotor. A 5 ml Hi-Trap chelating column (Amersham Bio-
sciences) previously loaded with nickel and equilibrated with buffer
A containing 20 mM imidazole was attached to an A ¨ KTA Explorer
system (Amersham Biosciences). The soluble fraction was applied
onto the column and washed with 30 ml buffer A containing 20 mM
imidazole followed by 50 ml buffer A containing 50 mM imidazole.
The protein was eluted with buffer A containing 500 mM imidazole
and passed to a Sephacryl S-200 gel-ﬁltration column (Amersham
Pharmacia) pre-equilibrated in 50 mM HEPES pH 7.4 containing
150 mM NaCl, 1 mM MnCl2 and 2 mM DTT for size-exclusion
chromatography. Fractions containing 1,3-PD-DH were identiﬁed by
SDS–PAGE, pooled and concentrated by ultraﬁltration to
55 mg ml
 1 in the same buffer.
2.2. Crystallization
Automated crystallization screening was carried out at 295 Kusing
sitting-drop vapour diffusion in 96-well plates (Greiner) using a
Cartesian Minibee nanolitre pipetting robot (Genomic Solutions)
and screens from Nextal Biotechnologies (Classics, PEGs, MbClass
and MbClass II). Each crystallization drop contained 150 nl protein
solution and 150 nl reservoir solution and was equilibrated against
150 ml reservoir solution. The most promising crystallization condi-
tions were found to be 0.1 M MES pH 6.5 with 15%(w/v) PEG 20K.
These conditions were optimized manually to 0.1 M MES pH 6.5 with
12%(w/v) PEG 20K. A screen of cationic additives added directly to
the crystallization drops using the optimized conditions was also
performed. The best results were obtained by the addition of CaCl2 to
the drop to a ﬁnal concentration of 10 mM (Fig. 1).
2.3. Data collection
Appropriate cryoprotecting conditions were obtained by soaking
crystals for 1 min in crystallization solution with 25%(v/v) glycerol.
Several data sets were collected using synchrotron radiation at
DESY, Hamburg or at the ESRF, Grenoble. The highest resolution
data collected to date (see statistics in Table 1) were obtained from a
crystal with dimensions of 0.15   0.15   0.15 mm vitriﬁed in liquid
nitrogen and were measured at ESRF beamline ID14-4. Diffraction
data were collected at 100 K using an Oxford Cryostream and an
ADSC Q4 CCD detector. Diffraction images were processed with
MOSFLM (Leslie, 2006) and experimental intensities were scaled
with SCALA from the CCP4 suite (Collaborative Computational
Project, Number 4, 1994). The data statistics are summarized in
Table 1.
3. Results and discussion
The dhaT gene from the human pathogen K. pneumoniae was
successfully cloned in E. coli and the encoded hexahistidine-tagged
1,3-PD-DH was puriﬁed to homogeneity by metal-chelating afﬁnity
chromatography. The best crystallization conditions included 12%
PEG 20K as a precipitant agent and 10 mM CaCl2 as an additive.
Crystals typically appeared in 8–24 h, reaching maximum dimensions
of 200   200   300 mm. The direct addition of CaCl2 to the crystal-
lization drop produced a signiﬁcant reduction in crystal mosaicity.
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Figure 1
1,3-PD-DH crystals grown in 0.1 M MES pH 6.5 with 12% PEG 20K, 10 mM CaCl2.
Table 1
Diffraction data-processing statistics.
Values in parentheses are for the highest resolution shell.
Source ESRF ID14-4
Space group P21
Unit-cell parameters (A ˚ ,  ) a = 91.44, b = 226.87,
c = 232.34,   = 92.71
Wavelength (A ˚ ) 0.939
No. of unique intensities 257983
Redundancy 3.5
Resolution (A ˚ ) 80–2.7 (2.85–2.7)
Completeness (%) 97.1 (92.2)
Rmerge† (%) 8.3 (36.8)
I/ (I) 12.1 (3.1)
† Rmerge =
P
h
P
i jIðh;iÞ h IðhÞij=
P
h
P
i Iðh;iÞ, where I(h, i) is the intensity of the ith
measurement of reﬂection h and hI(h)i is the mean value of I(h, i) for all i
measurements.Size-exclusion chromatography suggested that 1,3-PD-DH is a
decamer in solution (data not shown). In consequence, and taking
into account the presence of a peak in the self-rotation function
corresponding to twofold noncrystallographic symmetry, the crystals
probably contain two decamers in the asymmetric unit, with a VM
value of 3.07 A ˚ 3 Da
 1 and an estimated solvent content of 59%.
Structure solution by molecular replacement is currently under
way, using several homologous structures present in the PDB data-
base.
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